RYTM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RYTM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Rhythm Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was $-37.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was $-240.2 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Rhythm Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2024 was -256.46%. Rhythm Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -3,571.19%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. Rhythm Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -7.66%.
The historical data trend for Rhythm Pharmaceuticals's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
EBIT | Get a 7-Day Free Trial |
![]() |
![]() |
-134.00 | -69.61 | -175.92 | -170.22 | -239.65 |
Rhythm Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
EBIT | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-36.89 | -136.32 | -27.18 | -38.74 | -37.94 |
For the Biotechnology subindustry, Rhythm Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Rhythm Pharmaceuticals's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-240.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals (NAS:RYTM) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Rhythm Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:
ROC % (Q: Dec. 2024 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Sep. 2024 ) | + | Invested Capital (Q: Dec. 2024 )) | / count ) |
= | -165.02 * ( 1 - 0.21% ) | / | ( (65.466 | + | 62.954) | / 2 ) |
= | -164.673458 | / | 64.21 | |||
= | -256.46 % |
where
Invested Capital | (Q: Sep. 2024 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 363.572 | - | 55.37 | - | ( 298.39 | - | max(0, 97.605 | - | 340.341 | + | 298.39 | )) |
= | 65.466 |
Invested Capital | (Q: Dec. 2024 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 392.273 | - | 70.636 | - | ( 320.565 | - | max(0, 115.517 | - | 374.2 | + | 320.565 | )) |
= | 62.954 |
Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.
2. Joel Greenblatt's definition of Return on Capital:
Rhythm Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:
ROC (Joel Greenblatt) % | (Q: Dec. 2024 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Sep. 2024 | Q: Dec. 2024 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -151.74 | / | ( ( (4.389 + max(-55.654, 0)) | + | (4.109 + max(-61.882, 0)) ) | / | 2 ) |
= | -151.74 | / | ( ( 4.389 | + | 4.109 ) | / | 2 ) |
= | -151.74 | / | 4.249 | ||||
= | -3,571.19 % |
where Working Capital is:
Working Capital | (Q: Sep. 2024 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (19.306 | + | 13.895 | + | 8.75) | - | (55.37 | + | 1.286 | + | 40.949) |
= | -55.654 |
Working Capital | (Q: Dec. 2024 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (18.512 | + | 18.741 | + | 16.382) | - | (70.636 | + | 2.827 | + | 42.054) |
= | -61.882 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
Rhythm Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:
Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Dec. 2024 ) |
= | -240.174 | / | 3135.006 | |
= | -7.66 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Jennifer Chien | officer: EVP, Head of North America | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Joseph Shulman | officer: Chief Technical Officer | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
Hunter C Smith | officer: CFO and Treasurer | C/O GENESEE & WYOMING INC., 20 WEST AVENUE, DARIEN CT 06820 |
Pamela J. Cramer | officer: Chief Human Resources Officer | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
David P Meeker | director | C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810 |
Jennifer L Good | director | 15 GREAT RING ROAD, SANDY HOOK CT 06482 |
Lynn A. Tetrault | director | 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913 |
Christopher Paul German | officer: Corporate Controller & CAO | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
Yann Mazabraud | officer: EVP, Head of International | C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510 |
William T. Roberts | officer: Chief Accounting Officer | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
Linda Shapiro Manning | officer: Chief Medical Officer | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
Todd Foley | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116 |
Camille L Bedrosian | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Ra Capital Healthcare Fund Lp | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Nithya Desikan | officer: Chief Commercial Officer | 82 BAY STATE ROAD, BELMONT MA 02478 |
From GuruFocus
By Marketwired • 11-13-2024
By GuruFocus News • 02-14-2025
By Marketwired • 10-23-2024
By Marketwired • 11-14-2024
By Marketwired • 11-06-2024
By GuruFocus News • 11-07-2024
By GuruFocus News • 01-10-2025
By Marketwired • 10-08-2024
By Marketwired • 10-24-2024
By GuruFocus Research • 08-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.